June 24, 2020
According to the research report titled ‘Global Lopinavir and Ritonavir Market Size study (Impact of COVID 19 on Market Share), by Type (Tablet, Capsule, Oral solution), by Application (Adults, Children 14 days of age and older) and Regional Forecasts 2020-2026’, available with Market Study Report LLC, worldwide lopinavir & ritonavir market is predicted to showcase momentous growth during 2020-2026.
For the record, ritonavir and lopinavir are antiviral drugs which are used alongside other HIV medications in order to control human immunodeficiency virus present in the body. It helps in minimizing the amount of HIV infection in patient’s body, which subsequently boosts the body’s immunity.
Increased pervasiveness of HIV infection is a major factor driving the growth of lopinavir and ritonavir market. In fact, the U.S. Department of Health & Human Services states that the number of HIV patients totaled 37.9 million in the year 2018, which is an increase of 8 million since 2010.
Lopinavir & ritonavir not only help in improving the quality of life but also reduces the risk of other medical complications, including cancer and new infections, thereby fueling the market size. Additionally, rising prevalence of COVID-19 and ongoing clinical trials in order to test the effectiveness of lopinavir & ritonavir in treating the disease is also stimulating the industry outlook.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2663603/
In April 2020 for instance, researchers in Jin Yin-Tan Hospital in China apparently discovered that the combination of HIV antivirals lopinavir-ritonavir help in reducing the symptoms of COVID-19. However, adverse side-effects associated with these drugs may act as a restraining factor to the overall market growth.
As per type, lopinavir and ritonavir market is split into oral solution, capsule and tablet. In terms of application scope, the industry is divided into children 14 days of age & above and adults.
From the regional point of view, lopinavir and ritonavir industry in North America is expected to generate substantial revenues in the forthcoming years, primarily due to high occurrence of HIV infections and escalating government funding towards healthcare.
On the other hand, Asia-Pacific market is set to record considerable growth during the estimated timeframe. The growth is attributed to increasing number of HIV patients and improving healthcare infrastructure.
Rewine Pharmaceutical, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Hetero Drugs, Mylan N.V., Cipla Ltd., Hikma Pharmaceuticals, Lannett Co. Inc. and AbbVie Inc. are the major contenders in global lopinavir & ritonavir market.